GB202111035D0 - Therapy - Google Patents

Therapy

Info

Publication number
GB202111035D0
GB202111035D0 GBGB2111035.8A GB202111035A GB202111035D0 GB 202111035 D0 GB202111035 D0 GB 202111035D0 GB 202111035 A GB202111035 A GB 202111035A GB 202111035 D0 GB202111035 D0 GB 202111035D0
Authority
GB
United Kingdom
Prior art keywords
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2111035.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vestlandets Innovasjonsselskap AS
Original Assignee
Vestlandets Innovasjonsselskap AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vestlandets Innovasjonsselskap AS filed Critical Vestlandets Innovasjonsselskap AS
Priority to GBGB2111035.8A priority Critical patent/GB202111035D0/en
Publication of GB202111035D0 publication Critical patent/GB202111035D0/en
Priority to PCT/GB2022/052006 priority patent/WO2023007181A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
GBGB2111035.8A 2021-07-30 2021-07-30 Therapy Ceased GB202111035D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2111035.8A GB202111035D0 (en) 2021-07-30 2021-07-30 Therapy
PCT/GB2022/052006 WO2023007181A1 (en) 2021-07-30 2022-07-29 Phenothiazine antipsychotics for use in the treatment of glioblastoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2111035.8A GB202111035D0 (en) 2021-07-30 2021-07-30 Therapy

Publications (1)

Publication Number Publication Date
GB202111035D0 true GB202111035D0 (en) 2021-09-15

Family

ID=77651224

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2111035.8A Ceased GB202111035D0 (en) 2021-07-30 2021-07-30 Therapy

Country Status (2)

Country Link
GB (1) GB202111035D0 (en)
WO (1) WO2023007181A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA11722A (en) * 1998-12-02 2005-01-25 Pfizer Prod Inc Methods and compositions for restoring conformational stability of a protein of the p53 family.
US20060009506A1 (en) * 2004-07-09 2006-01-12 Odyssey Thera, Inc. Drugs for the treatment of neoplastic disorders
US20130289023A1 (en) * 2012-04-30 2013-10-31 Chi-Ying Huang Method for treating brain tumor
EP3574920A1 (en) * 2018-05-31 2019-12-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nupr1 inhibition for treating cancer

Also Published As

Publication number Publication date
WO2023007181A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
GB202001980D0 (en) Therapeutic mentods
GB202006960D0 (en) Therapeutic
GB202108303D0 (en) Therapy
GB202111288D0 (en) Combination therapy
GB202004189D0 (en) Combination therapy
GB202117706D0 (en) Therapy
GB202111035D0 (en) Therapy
GB202109893D0 (en) PeptiBAC therapy
GB202104427D0 (en) Therapy
GB202103164D0 (en) Therapy
GB202102211D0 (en) PeptiBAC therapy
GB202019218D0 (en) Therapy
GB202017554D0 (en) Therapy
GB202017598D0 (en) Therapy
GB202015778D0 (en) Therapy
GB202015780D0 (en) Therapy
GB202013834D0 (en) PeptiVAX therapy
GB202013824D0 (en) PeptiBAC therapy
GB202009039D0 (en) Therapy
GB202008031D0 (en) Therapy
GB202004629D0 (en) Therapy
GB202004013D0 (en) Therapy
GB202002639D0 (en) Therapy
GB202001905D0 (en) Therapy
IL304223A (en) Combination therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)